Asia On The Move: Pfizer Asia Clinical Head Joins APCER
This article was originally published in PharmAsia News
July saw Pfizer’s Asia clinical development head depart and Merck Serono pick a young Taiwanese executive as its president for Japan. Personnel changes also took place at Mitsubishi Tanabe and Zeria Pharma in Japan, and at Servier in China.
You may also be interested in...
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.
China’s Negative List for Foreign Investment explicitly bars “investment and application in human stem cells, genetic diagnosis, and treatment technologies.” But whether that applies to foreign pharma firms developing such modalities in the country remains unclear.
China biotechs appear increasingly interested in partnering with domestic counterparts amid signs the Chinese government's restrictive "COVID Zero" policies are likely to stay until well into 2023.